{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(1)"],"submitter":["de Laat W"],"funding":["LiGalli"],"pubmed_abstract":["Polymeric drug-releasing vaginal rings are useful for both local and systemic administration of drugs via the intravaginal route. Typically, they provide continuous sustained or controlled release of drug(s) over extended time periods, thereby avoiding overdose and improving adherence. This first-in-human study (EudraCT number: 2020-0050044-30) evaluated the pharmacokinetics, safety, and tolerability of a single dose of oxybutynin administered by a novel microprocessor-controlled vaginal ring (MedRing). Eight healthy female subjects received an electronically controlled single intravaginal dose of 3 mg oxybutynin hydrochloride (100 mg/mL) dissolved in 1:1 water/propylene glycol administered via MedRing. Following dosing, MedRing was kept <i>in situ</i> for up to 6 h. Blood samples were col"],"journal":["Drug delivery"],"pagination":["2180113"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9970198"],"repository":["biostudies-literature"],"pubmed_title":["First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring."],"pmcid":["PMC9970198"],"pubmed_authors":["de Laat W","Klarenbeek N","Stuurman R","Nickolson V","Huisman B","van Esdonk M","Pagan L","Malcolm RK","Wiegerinck M"],"additional_accession":[]},"is_claimable":false,"name":"First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring.","description":"Polymeric drug-releasing vaginal rings are useful for both local and systemic administration of drugs via the intravaginal route. Typically, they provide continuous sustained or controlled release of drug(s) over extended time periods, thereby avoiding overdose and improving adherence. This first-in-human study (EudraCT number: 2020-0050044-30) evaluated the pharmacokinetics, safety, and tolerability of a single dose of oxybutynin administered by a novel microprocessor-controlled vaginal ring (MedRing). Eight healthy female subjects received an electronically controlled single intravaginal dose of 3 mg oxybutynin hydrochloride (100 mg/mL) dissolved in 1:1 water/propylene glycol administered via MedRing. Following dosing, MedRing was kept <i>in situ</i> for up to 6 h. Blood samples were col","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-08-17T03:07:42.396Z","creation":"2025-04-07T00:32:08.227Z"},"accession":"S-EPMC9970198","cross_references":{"pubmed":["36815245"],"doi":["10.1080/10717544.2023.2180113"]}}